Alligator Bioscience Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Alligator Bioscience şirketinin toplam hissedar öz sermayesi SEK-76.0M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK91.8M ve SEK167.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 47.80m
Eşitlik	-SEK 76.00m
Toplam yükümlülükler	SEK 167.78m
Toplam varlıklar	SEK 91.78m

Son finansal sağlık güncellemeleri

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Aug 18

Recent updates

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

Dec 01

We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

Dec 21

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Jul 30

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Jan 06

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Aug 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ATORX negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: ATORX şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ATORX borçsuzdur.

Borcun Azaltılması: ATORX 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ATORX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: ATORX un, serbest nakit akışı her yıl % 6.9 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Alligator Bioscience Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Recent updates

Consensus revenue estimates fall by 17%

Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025

Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025

Third quarter 2024 earnings released: kr0.08 loss per share (vs kr0.083 loss in 3Q 2023)

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Price target increased by 18% to kr2.23

Consensus revenue estimates decrease by 31%

Second quarter 2024 earnings released: kr0.066 loss per share (vs kr0.19 loss in 2Q 2023)

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience Announces Completion of Enrollment in Mitazalimab Optimize-1 Study

Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial

Alligator Bioscience AB (publ) to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer

Consensus EPS estimates upgraded to kr0.46 loss, revenue downgraded

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

High number of new directors

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

New minor risk - Share price stability

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

No longer forecast to breakeven

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

New minor risk - Profitability

Third quarter 2023 earnings released

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Price target decreased by 19% to kr1.90

Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022)

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Consensus revenue estimates increase by 11%

Price target decreased by 36% to kr2.33

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Alligator Bioscience AB (Publ) Announces Management Changes

Alligator Bioscience Promotes Laura Von Schantz to Chief Technology Officer

Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021)

Alligator Bioscience Announces Positive Interim Results from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate

Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal

We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

High number of new directors

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.43 loss in 3Q 2021)

Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Alligator Bioscience Presents Additional Data from Mitazalimab OPTIMIZE-1 Phase 1B/2 Trial at AACR Special Conference on Pancreatic Cancer 2022

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: kr0.21 (vs kr0.41 loss in 2Q 2021)

Alligator Bioscience AB (publ), Annual General Meeting, May 03, 2023

Alligator Bioscience AB (publ) Appoints Sumeet Ambarkhane as Its Chief Medical Officer

Vice Chairman of the Board recently bought kr152k worth of stock

Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022

Alligator Bioscience Expands Its Board of Directors with the Appointment of Staffan Encrantz and Denise Goode

Consensus forecasts updated

Chief Executive Officer recently bought kr51k worth of stock

Price target decreased to kr2.80

Less than half of directors are independent

Alligator Bioscience AB (publ) Announces Completion of 600 Mg Dose Cohort for ATOR-1017, Dose-Escalation and Enrollment for 900 Mg Dose Cohort Commences

Consensus revenue estimates increase by 255%

Alligator Bioscience AB (publ) to Report Q3, 2022 Results on Oct 20, 2022

Alligator Bioscience Appoints Sumeet Ambarkhane as Chief Medical Officer

Alligator Bioscience Announces Optimize-1 Trial Update

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?